AllianceBernstein
ADMA icon

AllianceBernstein’s ADMA Biologics ADMA Stock Holding History

AllianceBernstein’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.68M Hold
297,883
– – ﹤0.01% 1874
2026
Q1 		$5.43M Buy
297,883
+3,300
+1% +$52.1K ﹤0.01% 1502
2025
Q4 		$5.37M Buy
294,583
+13,437
+5% +$226K ﹤0.01% 1507
2025
Q3 		$4.12M Buy
281,146
+8,623
+3% +$148K ﹤0.01% 1614
2025
Q2 		$4.96M Hold
272,523
– – ﹤0.01% 1483
2025
Q1 		$5.41M Sell
272,523
-2,740
-1% -$47.4K ﹤0.01% 1428
2024
Q4 		$4.72M Buy
275,263
+32,923
+14% +$619K ﹤0.01% 1520
2024
Q3 		$4.84M Sell
242,340
-1,130
-0.5% -$17.6K ﹤0.01% 1525
2024
Q2 		$2.72M Buy
243,470
+25,100
+11% +$211K ﹤0.01% 1781
2024
Q1 		$1.44M Buy
218,370
+30,770
+16% +$168K ﹤0.01% 2083
2023
Q4 		$848K Hold
187,600
– – ﹤0.01% 2354
2023
Q3 		$672K Hold
187,600
– – ﹤0.01% 2427
2023
Q2 		$692K Buy
187,600
+76,400
+69% +$283K ﹤0.01% 2477
2023
Q1 		$368K Hold
111,200
– – ﹤0.01% 2693
2022
Q4 		$431K Buy
111,200
+65,200
+142% +$201K ﹤0.01% 2704
2022
Q3 		$112K Buy
46,000
+20,800
+83% +$49.9K ﹤0.01% 3109
2022
Q2 		$50K Buy
+25,200
New +$49.6K ﹤0.01% 3173
2021
Q2 		– Sell
-82,000
Closed -$144K – 3320
2021
Q1 		$144K Sell
82,000
-700
-0.8% -$1.6K ﹤0.01% 3115
2020
Q4 		$161K Sell
82,700
-25,800
-24% -$54.2K ﹤0.01% 3040
2020
Q3 		$259K Sell
108,500
-76,400
-41% -$210K ﹤0.01% 2869
2020
Q2 		$542K Buy
184,900
+94,400
+104% +$271K ﹤0.01% 2562
2020
Q1 		$261K Buy
90,500
+66,900
+283% +$231K ﹤0.01% 2687
2019
Q4 		$94K Hold
23,600
– – ﹤0.01% 3045
2019
Q3 		$105K Hold
23,600
– – ﹤0.01% 3074
2019
Q2 		$91K Buy
+23,600
New +$104K ﹤0.01% 3092

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

AllianceBernstein's ADMA Position: Q2 2026 in Review

AllianceBernstein held its ADMA Biologics (ADMA) position steady in Q2 2026 at 297,883 shares worth $2.68M. The position accounts for ﹤0.01% of the portfolio, ranked #1874.

AllianceBernstein first reported a position in ADMA in Q2 2019 and has held it in 25 quarters since. The position peaked at $5.43M in Q1 2026. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • AllianceBernstein held 297,883 shares of ADMA Biologics worth $2.68M as of Q2 2026.
  • AllianceBernstein left its ADMA Biologics share count unchanged in Q2 2026.
  • ADMA Biologics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #1874 holding.
  • AllianceBernstein first reported a position in ADMA Biologics in Q2 2019 and has held it in 25 quarters since.
  • AllianceBernstein's ADMA Biologics position peaked at $5.43M in Q1 2026.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.